Drug Detail

Information about Erivedge

Generic Name	Vismodegib
IND	GDC-0449
Brand Name (US)	Erivedge
Manufacturer	Genentech
Drug Type
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	Basal cell carcinoma-metastatic or recurrent
Overall Strategy
Strategy	Block related tumor signal paths
Drug Category	SMO inhibitor

Erivedge (vismodegib) is a drug that was approved in January, 2012, for the treatment of advanced basal cell carcinoma. It is not approved for use in GIST and